POLYMYOSITIS

This study looks at the long-term safety and effectiveness of a medicine called dazukibart for people with dermatomyositis or polymyositis, which are rare diseases that cause muscle weakness and inflammation. About 211 adults who were in a previous dazukibart study will receive t…

This study tests a new treatment using a patient's own immune cells, modified to target and destroy faulty B cells that drive autoimmune diseases like lupus, scleroderma, and myositis. Up to 24 adults with active disease will receive the therapy after a short chemotherapy course.…

This early-stage study tests a new drug, SAR448501/DR-0201, in 62 adults with lupus or rheumatoid arthritis. The goal is to find the safest and most effective dose by checking side effects and how the drug works in the body. Participants will be followed for about 13 months, and …

This study aims to learn more about myositis, a group of diseases that cause muscle inflammation and damage. Researchers will study up to 1,200 children and adults with or without myositis to understand its causes, immune system changes, and related health problems. Participants …

This study is building a large database and sample bank from 5,000 adults with various rheumatic diseases like rheumatoid arthritis, lupus, and psoriatic arthritis. Researchers will use this information to find links between patient outcomes and biological markers. The goal is to…

This study looks at whether certain environmental exposures—like infections, stress, or sun exposure—are more common in people with anti-synthetase syndrome (a type of myositis with lung involvement) compared to other myositis patients and healthy volunteers. Researchers will col…

This study asks people living with rare myositis diseases (and their caregivers) what research questions matter most to them. Researchers will collect ideas through online surveys and forums. The goal is to create a patient-driven list of priorities to guide future studies and fu…